Gastroenteropancreatic Neuroendocrine Tumor – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
- Published Date : May 1, 2026
- Updated On : September 4, 2026
- Pages : 154
Gastroenteropancreatic Neuroendocrine Tumor Market Outlook
Thelansis’s “Gastroenteropancreatic Neuroendocrine Tumor Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastroenteropancreatic Neuroendocrine Tumor treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Gastroenteropancreatic Neuroendocrine Tumor Overview
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are heterogeneous malignancies arising from neuroendocrine cells of the gastrointestinal tract and pancreas, differing substantially in grade, differentiation, somatostatin-receptor expression, hormone secretion, and metastatic behavior. Somatostatin analogs remain important for hormone control and tumor-growth suppression in appropriate well-differentiated disease, while targeted therapy, chemotherapy, and peptide receptor radionuclide therapy (PRRT) are selected according to tumor biology and treatment history. PRRT with Lu-177-based agents has become a cornerstone for advanced somatostatin-receptor-positive NETs, with recent evidence supporting broader and more personalized use. The 2026 Phase 3 COMPETE trial directly compared Lu-177-edotreotide with everolimus in progressive SSTR-positive GEP-NETs, highlighting increasing emphasis on treatment sequencing and disease setting. Nevertheless, resistance, heterogeneous receptor expression, cumulative toxicity, and limited options after progression remain important unmet needs. Next-generation innovation is therefore extending the theranostic model through optimized dosimetry, combination strategies, and alpha-emitting radioligands that can deliver high-energy radiation to selected tumor cells. These approaches remain investigational and require validation of efficacy, safety, and patient selection. For stakeholders, GEP-NETs represent a high-value theranostic frontier where the next advances will depend on matching radionuclide properties and treatment sequencing to tumor biology while extending durable disease control.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Gastroenteropancreatic Neuroendocrine Tumor Market Outlook
Thelansis’s “Gastroenteropancreatic Neuroendocrine Tumor Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastroenteropancreatic Neuroendocrine Tumor treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Gastroenteropancreatic Neuroendocrine Tumor Overview
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are heterogeneous malignancies arising from neuroendocrine cells of the gastrointestinal tract and pancreas, differing substantially in grade, differentiation, somatostatin-receptor expression, hormone secretion, and metastatic behavior. Somatostatin analogs remain important for hormone control and tumor-growth suppression in appropriate well-differentiated disease, while targeted therapy, chemotherapy, and peptide receptor radionuclide therapy (PRRT) are selected according to tumor biology and treatment history. PRRT with Lu-177-based agents has become a cornerstone for advanced somatostatin-receptor-positive NETs, with recent evidence supporting broader and more personalized use. The 2026 Phase 3 COMPETE trial directly compared Lu-177-edotreotide with everolimus in progressive SSTR-positive GEP-NETs, highlighting increasing emphasis on treatment sequencing and disease setting. Nevertheless, resistance, heterogeneous receptor expression, cumulative toxicity, and limited options after progression remain important unmet needs. Next-generation innovation is therefore extending the theranostic model through optimized dosimetry, combination strategies, and alpha-emitting radioligands that can deliver high-energy radiation to selected tumor cells. These approaches remain investigational and require validation of efficacy, safety, and patient selection. For stakeholders, GEP-NETs represent a high-value theranostic frontier where the next advances will depend on matching radionuclide properties and treatment sequencing to tumor biology while extending durable disease control.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)